SOURCE-LINKED INTELLIGENCE

DNA methylation markers to predict treatment success of biologicals in Crohn’s disease.

CORDIS · observation · Publication date unknown

n CD. Specifically, we discovered and validated differential DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for 3 approved biologicals in CD. Through the use of machine learning algorithms, treatment response could be predicted with up to 93% accuracy for each biological for CD, and RA. METHYLOMICS is committed to bringing personalised treatment-selection in CD and other IMID to clinical practice. We have teamed up clinical, epigenetic, and DNA diagnostics experts, patient organisations, and companies across Europe, for further validation studies, develop a marketable rapid targeted methylation assay that we than validate in a unique prospective randomised clinical trial for CD. Efficiency and cost-effectiveness is assessed in great detail and regulatory approval is guided by experts to assure delivery of the first epigenetic kit personalised treatment of CD. Crohn's disease, epigenetic biomarkers, biological treatment response prediction, NGS targeted methylation assay development, machine learning, prospective clinical trial

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

9376995.25

unit

EUR